Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 01 2022 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2022
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrants name into English)
Three
International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS
FORM 6-K REPORT
On August 29, 2022 Kazia Therapeutics Limited (the
Company) filed its Annual Report to shareholders for the fiscal year ended June 30, 2022 with the Australian Stock Exchange (ASX), a copy of which is attached hereto as Exhibit 99.1. Also on August 29, 2022, the
Company filed its Appendix 4E, Appendix 4G, and Corporate Governance Statement with the ASX, copies of which are attached hereto as Exhibits 99.2, 99.3 and 99.4, respectively.
EXHIBIT LIST
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Kazia Therapeutics Limited (Registrant) |
|
/s/ Karen Krumeich |
Karen Krumeich |
Chief Financial Officer |
Date: 1 September 2022 |
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024